Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics
GET POWR RATINGS... FREE!
WVE POWR Grades
- WVE scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.67% of US stocks.
- The strongest trend for WVE is in Value, which has been heading up over the past 163 days.
- WVE's current lowest rank is in the Momentum metric (where it is better than 9.38% of US stocks).
WVE Stock Summary
- Of note is the ratio of Wave Life Sciences Ltd's sales and general administrative expense to its total operating expenses; merely 12.14% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for Wave Life Sciences Ltd comes in at 273.05%, a number that bests 97% of the US stocks we're tracking.
- The volatility of Wave Life Sciences Ltd's share price is greater than that of 86.54% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Wave Life Sciences Ltd, a group of peers worth examining would be FULC, IDYA, EIGR, ALPN, and DTIL.
- WVE's SEC filings can be seen here. And to visit Wave Life Sciences Ltd's official web site, go to www.wavelifesciences.com.
WVE Valuation Summary
- In comparison to the median Healthcare stock, WVE's EV/EBIT ratio is 104.78% lower, now standing at -1.4.
- WVE's price/sales ratio has moved down 2247.9 over the prior 71 months.
- Over the past 71 months, WVE's price/sales ratio has gone down 2247.9.
Below are key valuation metrics over time for WVE.
WVE's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- WVE has a Quality Grade of C, ranking ahead of 33.55% of graded US stocks.
- WVE's asset turnover comes in at 0.06 -- ranking 311th of 680 Pharmaceutical Products stocks.
- IONS, CORT, and CPIX are the stocks whose asset turnover ratios are most correlated with WVE.
The table below shows WVE's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
WVE Stock Price Chart Interactive Chart >
WVE Price/Volume Stats
|Current price||$2.18||52-week high||$12.17|
|Prev. close||$2.39||52-week low||$2.18|
|Day high||$2.43||Avg. volume||301,707|
|50-day MA||$3.48||Dividend yield||N/A|
|200-day MA||$5.36||Market Cap||128.26M|
Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.
Most Popular Stories View All
WVE Latest News Stream
|Loading, please wait...|
WVE Latest Social Stream
View Full WVE Social Stream
Latest WVE News From Around the Web
Below are the latest news stories about Wave Life Sciences Ltd that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Investment company Corsicana & Co. (Current Portfolio) buys Block Inc, Cummins Inc, SPDR Portfolio S&P 500 ETF, Teladoc Health Inc, LTC Properties Inc, sells iShares Core Total USD Bond Market ETF, Texas Capital Bancshares Inc, Deckers Outdoor Corp, Fifth Third Bancorp, Citizens Financial Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Corsicana & Co..
If you want to know who really controls Wave Life Sciences Ltd. ( NASDAQ:WVE ), then you'll have to look at the makeup...
Vintage Wine Estates marks eight years and one million meals donated through its Angels Share campaign to fight food insecurity
Vintage Wine Estates marks eight years and one million meals donated through its Angels Share campaign to fight food insecurityPR NewswireSANTA ROSA, Calif. 23, 2021 /PRNewswire/ -- Vintage Wine Estates, Inc.
Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences (WVE – Research Report) yesterday and set a price target of $13.00. The company's shares closed last Tuesday at $3.90, close to its 52-week low of $3.78. According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -5.7% and a 46.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Wave Life Sciences with a $8.50 average price target.
Wall Street brokerages expect Wave Life Sciences Ltd. (NASDAQ:WVE) to announce earnings per share of ($0.47) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Wave Life Sciences earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.72). Wave Life Sciences posted 
WVE Price Returns